Fundraising and Finding Success During Covid-19

Wednesday, September 16, 2020 (4:00 PM - 5:00 PM) (EDT)


In a sign that the medtech industry continues to show resilience in tough times, local medtech companies raised a combined $140 million in recent weeks. 

On September 16th join MassMEDIC, Vicarious Surgical, and CoreMap for a discussion on: Fundraising during a pandemic; Keeping teams focused on the end goal; and Crafting a story that sticks. These virtual gatherings are intended to keep our members up to date, share knowledge on current issues impacting healthcare and our industry, and provide a regular opportunity for networking and discussion. 

About Our Guests: Adam Sachs, Co-Founder and CEO, Vicarious Surgical. A 2013 graduate of MIT with a BS in Mechanical Engineering, Adam co-founded Vicarious Surgical in 2014 with Sammy Khalifa. Since 2010, he’s been an Emergency Medical Technician (EMT) on an ambulance in Cambridge serving the needs of the MIT community. Led by an experienced team of technologists, medical device professionals and physicians, and backed by technology luminaries including Bill Gates, Khosla Ventures, Eric Schmidt's Innovation Endeavors, Jerry Yang's AME Cloud Ventures, and Marc Benioff, Vicarious Surgical is the first surgical robot to be recognized with the FDA's Breakthrough classification. They aim to transport surgeons inside the patient to perform minimally invasive surgery using proprietary human-like surgical robots and virtual reality. 

Sarah Kalil, Co-Founder, President, and CEO, CoreMap. Sarah is a seasoned med-tech executive with over 25 years of successful product commercialization leadership roles and board level experience. Named one of the 20 “Medical Device Companies You Need To Know” in 2019 by Medical Design and Outsourcing, and a member of the MassMEDIC MedTech IGNITE 2019 Cohort, CoreMap is developing advanced diagnostic technology to enable electrophysiologists to make more informed therapeutic decisions and improve patient outcomes. It's technologies will allow for patient-specific treatments, because when treating patients with Atrial Fibrillation, ‘one size does not fit all.

Learn More

Event Contact
Brian Johnson
Powered By GrowthZone